The lymphotactin receptor is expressed in epithelial ovarian carcinoma and contributes to cell migration and proliferation

Molecular Cancer Research

Volumn 10, Issue 11, 2012, Pages 1419-1429

  Kim, Mijung ^a   Rooper, Lisa ^a   Xie, Jia ^a   Rayahin, Jamie ^a   Burdette, Joanna E ^a   Kajdacsy Balla, Andre A ^a   Barbolina, Maria V ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; LYMPHOTACTIN; LYMPHOTACTIN 1; LYMPHOTACTIN 2; LYMPHOTACTIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER CELL; CARCINOGENESIS; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; COLON DISEASE; CONTROLLED STUDY; DISTANT METASTASIS; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LIVER NODULE; METASTASIS; MOUSE; NONHUMAN; OVARY CARCINOMA; OVARY CELL; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN DISEASE;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES, C; FEMALE; HUMANS; LYMPHOKINES; MICE; MICE, NUDE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; SIALOGLYCOPROTEINS; TISSUE ARRAY ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84869223806     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0361     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
3. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;177:1053-64.
4. Cannistra SA, DeFranzo B, Niloff J, Ottensmeir C. Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res 1995;1:333-42.
5. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993;53:3830-8. (Pubitemid 23252051)
6. Casey RC, Skubitz AP. CD44 and beta1 integrins mediate ovarian carcinoma cellmigration toward extracellular matrix proteins. Clin Exp Metastasis 2000;18:67-75. (Pubitemid 32096052)
7. Khan SM, Funk HM, Thiolloy S, Lotan TL, Hickson J, Prins GS, et al. In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin Exp Metastasis 2010;27:185-96.
8. Barbolina MV, Kim M, Liu Y, Shepard J, Belmadani A, Miller RJ, et al. Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res 2010;8:653-64.
9. Kohn EC, Travers LA, Kassis J, Broome U, Klominek J. Malignant effusions are sources of fibronectin and other promigratory and proinvasive components. Diagn Cytopathol 2005;33:300-8. (Pubitemid 41598049)
10. Sood A, Moudgil A, Sood N, Kharay AS, Kaushal S, Narang AP. Role of fibronectin in diagnosis of malignant ascites. J Assoc Physicians India 1997;45:283-5. (Pubitemid 127519307)
11. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50. (Pubitemid 38868623)
12. Hedrick JA, Zlotnik A. Lymphotactin. Clin Immunol Immunopathol 1998;87:218-22. (Pubitemid 28285436)
13. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science 1994;266:1395-9.
14. Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi S, Yoshie O. Identification of single C motif-1/lymphotactin receptor XCR1. J Biol Chem 1998;273:16551-4. (Pubitemid 28311441)
15. Yoshida T, Imai T, Takagi S, Nishimura M, Ishikawa I, Yaoi T, et al. Structure and expression of two highly related genes encoding SCM- 1/human lymphotactin. FEBS Lett 1996;395:82-8. (Pubitemid 26342943)
16. Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu Y, Menon S, et al. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 1997;158:1533-40. (Pubitemid 127469505)
17. Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Güttler S, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity 2009;31:823-33.
18. Müller S, Dorner B, Korthaüer U, Mages HW, D'Apuzzo M, Senger G, et al. Cloning of ATAC, an activation-induced, chemokine-related molecule exclusively expressed in CD8+ T lymphocytes. Eur J Immunol 1995;25:1744-8.
19. Dorner B, Müller S, Entschladen F, Schröder JM, Franke P, Kraft R, et al. Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8(+) T cells. J Biol Chem 1997;272:8817-23. (Pubitemid 27147853)
20. Lei Y, Ripen AM, Ishimaru N, Ohigashi I, Nagasawa T, Jeker LT, et al. Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development. J Exp Med 2011;208:383-94.
21. Blaschke S, Middel P, Dorner BG, Blaschke V, Hummel KM, Kroczek RA, et al. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum 2003;48:1858-72. (Pubitemid 36828681)
22. Middel P, Thelen P, Blaschke S, Polzien F, Reich K, Blaschke V, et al. Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. Am J Pathol 2001;159:1751-61. (Pubitemid 33062518)
23. Stievano L, Piovan E, Amadori A. C and CX3C chemokines: cell sources and physiopathological implications. Crit Rev Immunol 2004;24:205-28. (Pubitemid 39419499)
24. Khurram SA, Whawell SA, Bingle L, Murdoch C, McCabe BM, Farthing PM. Functional expression of the chemokine receptor XCR1 on oral epithelial cells. J Pathol 2010;221:153-63.
25. Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F, Burdette JE. Glycogen synthase kinase 3b inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs 2011;22:978-85.
26. Auersperg N. The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol 2011;30:12-21.
27. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-7.
28. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26:5284-93.
29. Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PloS ONE 2010;5:e10358.
30. Kennedy J, Kelner GS, Kleyensteuber S, Schall TJ, Weiss MC, Yssel H, et al. Molecular cloning and functional characterization of human lymphotactin. J Immunol 1995;155:203-9.
31. Peterson FC, Elgin ES, Nelson TJ, Zhang F, Hoeger TJ, Linhardt RJ, et al. Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem 2004;279:12598-604. (Pubitemid 38445831)
32. Yoshida T, Ishikawa I, Ono Y, Imai T, Suzuki R, Yoshie O. An activation-responsive element in single C motif-1/lymphotactin promoter is a site of constitutive and inducible DNA-protein interactions involving nuclear factor of activated T cell. J Immunol 1999;163:3295-303. (Pubitemid 29431831)
33. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev;21:27-39.
34. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008;122:91-9. (Pubitemid 350209982)
35. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996;2:1090-5. (Pubitemid 26338627)
36. Gao JQ, Sugita T, Kanagawa N, Iida K, Okada N, Mizuguchi H, et al. Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector. Biol Pharm Bull 2005;28:1066-70. (Pubitemid 40880316)
37. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326-31. (Pubitemid 41746944)
38. Nelson DS, Nelson M. Evasion of host defences by tumours. Immunol Cell Biol 1987;65:287-304.
39. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003;2:581-7. (Pubitemid 37361749)
40. Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 2010;54:4137-42.
41. Jerath MR, Liu P, Struthers M, Demartino JA, Peng R, Peterson LB, et al. Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation. Thromb J 2010;8:14.
42. Guo L, Cui ZM, Zhang J, Huang Y. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6correlate with lymph node metastasis in epithelial ovarian carcinoma. Chin J Cancer 2011;30:336-43.
43. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011;71:5522-34.
44. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930-8. (Pubitemid 35204756)